S9 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mortality; Analysis: subgroups by intervention implemented.

Study	Experimental Events Total B	Control Events Total	Risk Ratio	Weight Weigh RR 95%-CI (fixed) (random	
Intervention = Ivermed Mahmud et al Hashim HA et al Fixed effect model Random effects mode Heterogeneity: $l^2 = 0\%$, t ²	0 183 2 70 253	ne 3 180 - 6 70 250	*	0.14 [0.01; 2.70] 3.8% 3.19 0.33 [0.07; 1.60] 6.5% 7.89 0.26 [0.07; 1.03] 10.3% 0.28 [0.07; 1.10] 10.9%	6
Intervention = Ivermed Elgazzar et al (mild) Elgazzar et al (severe) Niaee et al Kirti et al Shahbaznejad et al Okumus et al Beltran et al Lopez-Medina et al Bermejo Galan et al Abd-Elsalam et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 53\%$,	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	4 100 - 20 100 11 60 4 57 - 0 34 9 30 8 70 1 198 25 115 4 82 3 251 1097		0.11 [0.01; 2.04] 4.9% 3.29 0.10 [0.02; 0.42] 21.7% 8.7% 0.18 [0.06; 0.55] 15.9% 11.29 0.12 [0.01; 2.09] 4.8% 3.29 0.12 [0.01; 2.09] 4.8% 3.29 0.12 [0.01; 2.09] 4.8% 3.29 0.12 [0.01; 2.09] 4.8% 3.29 0.67 [0.27; 1.64] 0.5% 2.89 0.67 [0.27; 1.64] 9.7% 13.09 1.22 [0.43; 3.45] 5.9% 11.79 0.33 [0.01; 8.05] 1.6% 2.79 1.04 [0.57; 1.91] 17.1% 15.89 0.75 [0.17; 3.25] 4.3% 8.59 1.34 [0.30; 5.92] 3.2% 8.39 0.53 [0.29; 0.99] 89.19	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Fixed effect model Random effects mode Heterogeneity: $I^2 = 48\%$, Test for subgroup different Test for subgroup different	$t^2 = 0.4356, p = 0.0$ ces (fixed effect): c	² ₁ = 0.95, df = 10(0.50 [0.36; 0.69] 100.0% 0.50 [0.28; 0.88] 100.0% 0	-

S10 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mortality; Analysis: subgroups by control implemented.

Study	Experimental Events Total Ev	Control vents Total	Risk Ratio	Weight RR 95%-CI (fixed) (Weight random)
Control = SOC Mahmud et al Hashim HA et al Kirti et al Shahbaznejad et al Okumus et al Lopez-Medina et al Abd-Elsalam et al Vallejos et al Fixed effect model	0 183 2 70 0 55 1 35 6 30 0 200 3 82 4 250 905	3 180 - 6 70 4 57 - 0 34 9 30 1 198 4 82 3 251 902		0.14 [0.01; 2.70] 3.8% 0.33 [0.07; 1.60] 6.5% 0.12 [0.01; 2.09] 4.8% 2.92 [0.12; 69.14] 0.5% 0.67 [0.27; 1.64] 9.7% 0.33 [0.01; 8.05] 1.6% 0.75 [0.17; 3.25] 4.3% 1.34 [0.30; 5.92] 3.2% 0.56 [0.32; 0.98] 34.6%	3.1% 7.8% 3.2% 2.8% 13.0% 2.7% 8.5% 8.5%
Random effects mode Heterogeneity: $I^2 = 0\%$, t Control = HCQ				0.62 [0.35; 1.10]	49.4%
Elgazzar et al (mild) Elgazzar et al (severe) Niaee et al Beltran et al Bermejo Galan et al Fixed effect model Random effects model Heterogeneity: $I^2 = 78\%$,		4 100 - 20 100 11 60 8 70 25 115 445		0.11 [0.01; 2.04] 4.9% 0.10 [0.02; 0.42] 21.7% 0.18 [0.06; 0.55] 15.9% 1.22 [0.43; 3.45] 5.9% 1.04 [0.57; 1.91] 17.1% 0.47 [0.31; 0.70] 65.4% 0.38 [0.12; 1.14]	3.2% 8.7% 11.2% 11.7% 15.8% 50.6%
Fixed effect model Random effects mode Heterogeneity: $l^2 = 48\%$, Test for subgroup differen	$t^2 = 0.4356, p = 0.03$ ces (fixed effect): c_1^2	= 0.28, df = 10		0.50 [0.36; 0.69] 100.0% 0.50 [0.28; 0.88]	 100.0%

Test for subgroup differences (random effects): $c_1^2 = 0.61$, df = 1 (p = 0.43)

S11 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mortality; Analysis: subgroups by disease severity.

Study	Experimental Events Total Eve	Control ents Total	Risk Ratio	RR 95%-	Weight Weig Cl (fixed) (rando	•
Severity = Mild to mod Mahmud et al Elgazzar et al (mild) Kirti et al Lopez-Medina et al Abd-Elsalam et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t	0 183 0 100 0 55 0 200 3 82 4 250 870	3 180 4 100 4 57 1 198 4 82 3 251 868		0.14 [0.01; 2.7 0.11 [0.01; 2.0 0.12 [0.01; 2.0 0.33 [0.01; 8.0 0.75 [0.17; 3.2 1.34 [0.30; 5.9 0.43 [0.20; 0.9 0.54 [0.23; 1.2	4] 4.9% 3.1 6] 4.8% 3.1 5] 1.6% 2.1 5] 4.3% 8.1 2] 3.2% 8.1 8] 22.7% 8.1	1% 2% 2% 5% 3% 0%
Severity = Mixed Hashim HA et al Niaee et al Shahbaznejad et al Beltran et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 60\%$,		6 70 11 60 0 34 8 70 234		0.33 [0.07; 1.6 0.18 [0.06; 0.5 2.92 [0.12; 69.1 1.22 [0.43; 3.4 0.48 [0.26; 0.8 0.53 [0.16; 1.6	5] 15.9% 11.3 4] 0.5% 2.3 5] 5.9% 11.3 3] 28.8%	8% 7%
Severity = Severe to c Elgazzar et al (severe) Okumus et al Bermejo Galan et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 80\%$,	2 100 6 30 12 53 183	20 100 9 30 25 115 245		0.10 [0.02; 0.4 0.67 [0.27; 1.6 1.04 [0.57; 1.9 0.55 [0.35; 0.8 0.48 [0.14; 1.5	4] 9.7% 13.0 1] 17.1% 15.8 5] 48.5%	8%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 48\%$, Test for subgroup differen	$t^2 = 0.4356, p = 0.03$ ces (fixed effect): $c_2^2 =$	1347 0.31, df = 20	(@ \$ 0.86)1 1 10 10	0.50 [0.36; 0.6 0.50 [0.28; 0.8	-	 0%

Test for subgroup differences (random effects): $c_2^2 = 0.02$, df = 2 (p = 0.99)

S12 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mechanical ventilation; Analysis: subgroups by intervention implemented.

Study	Experim Events		Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Intervention = Ivermed	ctin								
Krolewiecki et al	1	20	0	12		- 1.83	[0.08; 41.52]	2.2%	2.5%
Kirti et al	1	55	5	57		0.21	[0.03; 1.72]	17.7%	5.5%
Shahbaznejad et al	2	35	1	34		1.94	[0.18; 20.45]	3.7%	4.5%
Bermejo Galan et al	12	53	24	115	- <u>+</u> -	1.08	[0.59; 2.00]	54.7%	66.2%
Abd-Elsalam et al	3	82	3	82		1.00	[0.21; 4.81]	10.8%	10.0%
Vallejos et al	4	250	3	251		1.34	[0.30; 5.92]	10.8%	11.2%
Fixed effect model		495		551		1.00	[0.61; 1.62]	100.0%	
Random effects mode					\Leftrightarrow	1.05	[0.64; 1.72]		100.0%
Heterogeneity: $I^2 = 0\%$, t	$p^2 = 0, p = 0$.73							
Fixed effect model		495		551	\downarrow	1.00	[0.61; 1.62]	100.0%	
Random effects mode	-					1.05	[0.64; 1.72]		100.0%
Heterogeneity: $I^2 = 0\%$, t			_						
Test for subgroup differen	ces (fixed e	effect):	$C_0^2 = 0.00$, df = 0	$(p = NA) 0.5 \ 1 \ 2 10$				
Test for subaroup differen	ces (rando	m effe	$cts): c_{2}^{2} = 0$	0 00 df	= 0 (n = NA)				

Test for subgroup differences (random effects): $c_0^2 = 0.00$, df = 0 (p = NA)

S13 Figure Comparison: ivermectin vs. Standard of care; Outcome: mechanical ventilation; Analysis: subgroups by control implemented.

Study	Experiment Events To		ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Control = SOC Krolewiecki et al Kirti et al Shahbaznejad et al Abd-Elsalam et al Vallejos et al Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, t^2	1 2 3 4 2 4	20 0 55 5 35 1 82 3 50 3 42	12 57 - 34 82 251 436		0.21 [0 1.94 [0. 1.00 [0 1.34 [0 0.89 [0	08; 41.52] 0.03; 1.72] 18; 20.45] 0.21; 4.81] 0.30; 5.92] 0.40; 1.98] 0.41; 2.29]	2.2% 17.7% 3.7% 10.8% 10.8% 45.3%	2.5% 5.5% 4.5% 10.0% 11.2% 33.8%
Control = HCQ Bermejo Galan et al Fixed effect model Random effects model Heterogeneity: not applica		53 24 53	115 115	+ \ 	1.08 [0	.59; 2.00] .59; 2.00] .59; 2.00]	54.7% 54.7% 	66.2% 66.2%
Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, t^2		95	551		-	.61; 1.62] .64; 1.72]	100.0% 	 100.0%

Test for subgroup differences (fixed effect): $c_1^2 = 0.15$, df = 1 (p = 0.70) 0.5 1 2 Test for subgroup differences (random effects): $c_1^2 = 0.04$, df = 1 (p = 0.84) 10

S14 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mechanical ventilation; Analysis: subgroups by disease severity.

subgroups by disease s	Experin		Co	ontrol				Weight	Weight
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(fixed)	(random)
Severity = Mild to mode	rate								
Krolewiecki et al	1	20	0	12		1.83	[0.08; 41.52]	2.2%	2.5%
Kirti et al	1	55		57		0.21	[0.03; 1.72]	17.7%	5.5%
Abd-Elsalam et al	3	82	3	82		1.00	[0.21; 4.81]	10.8%	10.0%
Vallejos et al	4	250	3	251		1.34	[0.30; 5.92]	10.8%	11.2%
Fixed effect model		407		402		0.80	[0.34; 1.88]	41.6%	
Random effects model						0.88	[0.35; 2.19]		29.3%
Heterogeneity: $I^2 = 0\%$, $t^2 =$	= 0, p = 0).50							
Severity = Mixed									
Shahbaznejad et al	2	35	1	34		1.94	[0.18; 20.45]	3.7%	4.5%
Fixed effect model		35		34		1.94	[0.18; 20.45]	3.7%	
Random effects model						1.94	[0.18; 20.45]		4.5%
Heterogeneity: not applicab	le								
Severity = Severe to crit	tical								
Bermejo Galan et al	12	53	24	115		1.08	[0.59; 2.00]	54.7%	66.2%
Fixed effect model		53		115	\Leftrightarrow	1.08	[0.59; 2.00]	54.7%	
Random effects model					\Leftrightarrow	1.08	[0.59; 2.00]		66.2%
Heterogeneity: not applicab	le								
Fixed effect model		495		551	\diamond	1.00	[0.61; 1.62]	100.0%	
Random effects model						1.05	[0.64; 1.72]		100.0%
Heterogeneity: $I^2 = 0\%$, $t^2 = 0\%$									
Test for subgroup difference									
Test for subgroup difference	es (rando	m effec	cts): c ₂ ² = 0	0.42, df	= 2 (<i>p</i> = 0.81)				

S15 Figure. Comparison: ivermectin vs. Standard of care; Outcome: symptom resolution or improvement; Analysis: subgroups by intervention implemented.

Study	Experim Events		Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Intervention = Ivermec Chowdhury et al Mahmud et al Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, t^2	50 141 = 0, <i>p</i> = 0	60 183 243	ne 40 113	56 180 236		1.23 1.21	[0.95; 1.43] [1.07; 1.41] [1.08; 1.36] [1.08; 1.35]	6.3% 17.3% 23.6% 	8.6% 10.2% 18.8%
Intervention = Ivermec Elgazzar et al (mild) Elgazzar et al (severe) Chachar et al Kirti et al Mohan et al Okumus et al Beltran et al Lopez-Medina et al Kishoria et al Faisal et al Fixed effect model Random effects model Heterogeneity: $I^2 = 82\%$, t	99 94 16 46 74 22 32 164 8 48	100 100 25 55 80 30 36 200 19 50 695	74 50 15 51 39 16 64 156 6 42	100 100 25 57 45 30 70 198 16 50 691		1.88 1.07 0.93 1.07 1.38 0.97 1.04 - 1.12 1.14 1.17	$ \begin{bmatrix} 1.19; 1.51 \\ 1.54; 2.30 \end{bmatrix} \\ \begin{bmatrix} 0.69; 1.65 \\ 0.81; 1.08 \end{bmatrix} \\ \begin{bmatrix} 0.94; 1.22 \end{bmatrix} \\ \begin{bmatrix} 0.92; 2.05 \\ 0.85; 1.11 \end{bmatrix} \\ \begin{bmatrix} 0.94; 1.15 \\ 0.49; 2.56 \end{bmatrix} \\ \begin{bmatrix} 1.00; 1.31 \end{bmatrix} \\ \begin{bmatrix} 1.11; 1.24 \\ 1.02; 1.32 \end{bmatrix} $	11.2% 7.6% 7.6% 7.6% 2.4% 6.6% 23.8% 1.0% 6.4% 76.4%	10.7% 8.5% 4.1% 10.0% 10.4% 4.5% 10.2% 11.1% 1.5% 10.3% 81.2%
Fixed effect model Random effects model Heterogeneity: $I^2 = 79\%$, t Test for subgroup difference Test for subgroup difference	$e^{2} = 0.0244$ ces (fixed e	effect):	$c_1^2 = 0.22,$				[1.13; 1.24] [1.05; 1.30]	100.0% 	 100.0%

Test for subgroup differences (fixed effect): $c_1^2 = 0.22$, df = 1 ($p \oplus .6.64$) Test for subgroup differences (random effects): $c_1^2 = 0.21$, df = 1 (p = 0.65)

S16 Figure. Comparison: ivermectin vs. Standard of care; Outcome: symptom resolution or improvement; Analysis: subgroups by control implemented.

	Experim			ntrol				Weight	Weight
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(fixed)	(random)
Control = HCQ									
Chowdhury et al	50	60	40	56	++	1.17	[0.95; 1.43]	6.3%	8.6%
Elgazzar et al (mild)	99	100	74	100		1.34	[1.19; 1.51]	11.2%	10.7%
Elgazzar et al (severe)	94	100	50	100	· · · · · · · · · · · · · · · · · · ·	1.88	[1.54; 2.30]	7.6%	8.5%
Beltran et al	32	36	64	70		0.97	[0.85; 1.11]	6.6%	10.2%
Fixed effect model		296		326	\diamond	1.36	[1.25; 1.48]	31.7%	
Random effects model						1.29	[0.99; 1.70]		38.0%
Heterogeneity: $I^2 = 92\%$, t	² = 0.0690), p < 0	0.01						
Control = SOC									
Mahmud et al	141	183	113	180		1.23	[1.07; 1.41]	17.3%	10.2%
Chachar et al	16	25	15	25		1.07	[0.69; 1.65]	2.3%	4.1%
Kirti et al	46	55	51	57	— — —	0.93	[0.81; 1.08]	7.6%	10.0%
Mohan et al	74	80	39	45	- = 3	1.07	[0.94; 1.22]	7.6%	10.4%
Okumus et al	22	30	16	30		1.38	[0.92; 2.05]	2.4%	4.5%
Lopez-Medina et al	164	200	156	198		1.04	[0.94; 1.15]	23.8%	11.1%
Kishoria et al	8	19	6	16		— 1.12	[0.49; 2.56]	1.0%	1.5%
Faisal et al	48	50	42	50	- <u></u> -	1.14	[1.00; 1.31]	6.4%	10.3%
Fixed effect model		642		601	\diamond	1.10	[1.04; 1.17]	68.3%	
Random effects model					\diamond	1.09	[1.01; 1.17]		62.0%
Heterogeneity: $I^2 = 32\%$, t	$^{2} = 0.0032$	2, p = 0).17						
Fixed effect model		938		927	*	1.18	[1.13; 1.24]	100.0%	
Random effects model					\diamond	1.17	[1.05; 1.30]		100.0%
Heterogeneity: $I^2 = 79\%$, t ²	² = 0.0244	4, p < 0	0.01						
Test for subgroup differenc				3, df = 1	(<i>p</i> 0,50.01) 1 2				
Test for subgroup differenc									

Test for subgroup differences (random effects): $c_1^2 = 1.49$, df = 1 (p = 0.22)

S17 Figure. Comparison: ivermectin vs. Standard of care; Outcome: symptom resolution or improvement; Analysis: subgroups by disease severity.

Study	Experime Events			ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Severity = Mild to mod Chowdhury et al Mahmud et al Elgazzar et al (mild) Chachar et al Kirti et al Mohan et al Lopez-Medina et al Kishoria et al Faisal et al Fixed effect model Random effects model Heterogeneity: I ² = 59%, t	50 141 99 16 46 74 164 8 48	60 183 100 25 55 80 200 19 50 772	40 113 74 15 51 39 156 6 42	56 180 100 25 57 45 198 16 50 727		1.23 1.34 1.07 0.93 1.07 1.04 - 1.12 1.14 1.13	[0.95; 1.43] [1.07; 1.41] [1.19; 1.51] [0.69; 1.65] [0.81; 1.08] [0.94; 1.22] [0.94; 1.15] [0.49; 2.56] [1.00; 1.31] [1.07; 1.19] [1.03; 1.22]	6.3% 17.3% 11.2% 2.3% 7.6% 23.8% 1.0% 6.4% 83.4%	8.6% 10.2% 10.7% 4.1% 10.0% 10.4% 11.1% 1.5% 10.3% 76.7%
Severity = Severe to cr Elgazzar et al (severe) Okumus et al Fixed effect model Random effects model Heterogeneity: $l^2 = 47\%$, t	94 22	100 30 130	50 16	100 30 130		1.38 1.76	[1.54; 2.30] [0.92; 2.05] [1.47; 2.10] [1.26; 2.26]	7.6% 2.4% 10.0% 	8.5% 4.5% 13.1%
Severity = Mixed Beltran et al Fixed effect model Random effects model Heterogeneity: not applica		36 36	64	70 70		0.97	[0.85; 1.11] [0.85; 1.11] [0.85; 1.11]	6.6% 6.6% 	10.2% 10.2%
Fixed effect model Random effects model Heterogeneity: $I^2 = 79\%$, t Test for subgroup difference Tost for subgroup difference	$e^{2} = 0.0244$, ces (fixed ef	ffect):	$c_2^2 = 27.5$				[1.13; 1.24] [1.05; 1.30]	100.0% 	 100.0%

Test for subgroup differences (random effects): $c_2^2 = 11.68$, df = 2 (p < 0.01)

S18 Figure. Comparison: ivermectin vs. Standard of care; Outcome: symptom resolution or improvement; Analysis: subgroups by outcome measurement time frame.

Study	Experim Events		Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Follow: < 14 days					5				
Chowdhury et al	50	60	40	56		1 17	[0.95; 1.43]	6.3%	8.6%
Chachar et al	16	25	15	25			[0.69; 1.65]	2.3%	4.1%
Kirti et al	46	55	51	57			[0.81; 1.08]	7.6%	10.0%
Okumus et al	22	30	16	30			[0.92; 2.05]	2.4%	4.5%
Beltran et al	32	36	64	70	<u>}</u>		[0.85; 1.11]	6.6%	10.2%
Kishoria et al	8	19	6	16		- 1.12	[0.49; 2.56]	1.0%	1.5%
Faisal et al	48	50	42	50		1.14	[1.00; 1.31]	6.4%	10.3%
Fixed effect model		275		304	\diamond	1.08	[0.99; 1.17]	32.5%	
Random effects mode						1.06	[0.96; 1.16]		49.1%
Heterogeneity: $I^2 = 30\%$, f Follow: > or = 14 days	² = 0.0044	н, <i>р</i> = 0	0.20						
Mahmud et al	141	183	113	180		1.23	[1.07; 1.41]	17.3%	10.2%
Elgazzar et al (mild)	99	100	74	100		1.34	[1.19; 1.51]	11.2%	10.7%
Elgazzar et al (severe)	94	100	50	100		1.88	[1.54; 2.30]	7.6%	8.5%
Mohan et al	74	80	39	45	- = 2	1.07	[0.94; 1.22]	7.6%	10.4%
Lopez-Medina et al	164	200	156	198		1.04	[0.94; 1.15]	23.8%	11.1%
Fixed effect model		663		623		1.24	[1.16; 1.31]	67.5%	
Random effects mode						1.26	[1.06; 1.50]		50.9%
Heterogeneity: $I^2 = 89\%$,	² = 0.0338	8, <i>p</i> < 0	0.01						
Fixed effect model		938		927	\$		[1.13; 1.24]	100.0%	
Random effects model						1.17	[1.05; 1.30]		100.0%
Heterogeneity: $I^2 = 79\%$, t									
Test for subgroup difference									

Test for subgroup differences (fixed effect): $c_1^2 = 7.10$, df = 1 (p 0.6.01) Test for subgroup differences (random effects): $c_1^2 = 3.13$, df = 1 (p = 0.08)

S19 Figure. Comparison: ivermectin vs. Standard of care; Outcome: hospitalization; Analysis: subgroups by intervention implemented.

Study	Experimental Events Total E	Control vents Total	Risk Ratio	Weight RR 95%-CI (fixed) (ra	Weight andom)
Intervention = Ivermed Samaha et al Lopez-Medina et al Biber et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $J^2 = 0\%$, t	0 50 4 200 1 47 14 250 547	3 50 6 198 2 42 21 251 541		0.14 [0.01; 2.70] 10.7% 0.66 [0.19; 2.30] 18.5% 0.45 [0.04; 4.75] 6.5% 0.67 [0.35; 1.29] 64.3% 0.60 [0.35; 1.03] 100.0% 0.62 [0.36; 1.07]	3.5% 19.5% 5.5% 71.5% 100.0%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t Test for subgroup differen Test for subgroup differen	$^{2} = 0, p = 0.77$ nces (fixed effect): c_{0}^{2}			0.60 [0.35; 1.03] 100.0% 0.62 [0.36; 1.07]	 100.0%

Test for subgroup differences (random effects): $c_0^2 = 0.00$, df = 0 (p = NA)

S20 Figure. Comparison: ivermectin vs. Standard of care; Outcome: hospitalization; Analysis: subgroups by control implemented.

Study	Experimer Events To		Control s Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Control = SOC Samaha et al Lopez-Medina et al Biber et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t	1 14 2	547	3 50 - 6 198 2 42 1 251 541	*	0.66 0.45 0.67 0.60	[0.01; 2.70] [0.19; 2.30] [0.04; 4.75] [0.35; 1.29] [0.35; 1.03] [0.36; 1.07]	10.7% 18.5% 6.5% 64.3% 100.0%	3.5% 19.5% 5.5% 71.5% 100.0%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t Test for subgroup differen Test for subgroup differen	$p^2 = 0, p = 0.77$ aces (fixed effe	ect): $c_0^2 = 0.0$				[0.35; 1.03] [0.36; 1.07]	100.0% 	 100.0%

S21 Figure. Comparison: ivermectin vs. Standard of care; Outcome: hospitalization; Analysis: subgroups by disease severity.

Study	Experime Events			ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Severity = Mild to mod Samaha et al Lopez-Medina et al Biber et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t	0 4 1 14	50 200 47 250 547 77	3 6 2 21	50 - 198 42 251 541		0.66 0.45 0.67 0.60	[0.01; 2.70] [0.19; 2.30] [0.04; 4.75] [0.35; 1.29] [0.35; 1.03] [0.36; 1.07]	10.7% 18.5% 6.5% 64.3% 100.0%	3.5% 19.5% 5.5% 71.5% 100.0%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t Test for subgroup differen Test for subgroup differen	$p^2 = 0, p = 0.$	ffect):	$c_0^2 = 0.00,$ ets): $c_0^2 = 0$	541 df = (0) 0.00, df	φ 1= NA 0 .1 1 10 100 = 0 (ρ = NA)	0.62	[0.35; 1.03] [0.36; 1.07]	100.0% 	 100.0%

S22 Figure. Comparison: ivermectin vs. Standard of care; Outcome: infection; Analysis: subgroups by intervention implemented.

Study	Experimental Events Total	Control Events Total	Risk Ratio	RR 95	Weight %-CI (fixed)	-
Intervention = Ivermectin Shouman et al Elgazzar et al (prophylaxis Seet et al Fixed effect model Random effects model Heterogeneity: I^2 = 88%, t^2 =	15 203) 2 100 32 617 920	59 101 10 100 64 619 820		0.13 [0.08; 0.20 [0.04; 0.50 [0.33; 0.29 [0.21; 0.24 [0.08;	0.89] 5.6% 0.76] 36.0% 0.39] 85.9%	16.9%
Intervention = Ivermectin	+ iota-carrage	enan				
Chahla et al Fixed effect model Random effects model Heterogeneity: not applicable	4 117 117	25 117 117		0.16 [0.06; 0.16 [0.06; 0.16 [0.06;	0.45] 14.1%	22.7% 22.7%
Fixed effect model Random effects model Heterogeneity: $I^2 = 84\%$, $t^2 =$ Test for subgroup differences	(fixed effect): $c_1^2 =$			0.22 [0.09;	0.36] 100.0% 0.53]	 100.0%

Test for subgroup differences (random effects): $c_1^2 = 0.29$, df = 1 (p = 0.59)

S23 Figure. Comparison: ivermectin vs. Standard of care; Outcome: infection; Analysis: subgroups by control implemented.

Study	Experime Events			ntrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Control = SOC Shouman et al Chahla et al Seet et al Fixed effect model Random effects model Heterogeneity: I^2 = 89%, t^2 =	15 4 32	203 117 617 937 < 0.01	59 25 64	101 117 619 837		0.16 0.50 0.27	[0.08; 0.21] [0.06; 0.45] [0.33; 0.76] [0.21; 0.37] [0.08; 0.62]	44.3% 14.1% 36.0% 94.4%	29.6% 22.7% 30.8% 83.1%
Control = HCQ Elgazzar et al (prophylaxis Fixed effect model Random effects model Heterogeneity: not applicable	,	100 100	10	100 100		0.20	[0.04; 0.89] [0.04; 0.89] [0.04; 0.89]	5.6% 5.6% 	16.9% 16.9%
Fixed effect model Random effects model Heterogeneity: $I^2 = 84\%$, $t^2 =$ Test for subgroup differences Test for subgroup differences	0.6058, <i>p</i> · (fixed effec	t): c ₁ ² =	= 0.17, df	937 = 1 (p = , df = 1	= 0068) 0.5 1 2 10 (p = 0.90)		[0.20; 0.36] [0.09; 0.53]	100.0% 	 100.0%

S24 Figure. Comparison: ivermectin vs. Standard of care; Outcome: viral clearance; Analysis: subgroups by intervention implemented.

random)
5.4%
19.7%
1.7%
26.9%
4.4%
4.8%
6.9%
6.3%
9.9%
3.2%
2.5%
2.8%
16.3%
16.0%
73.1%
100.0%

S25 Figure. Comparison: ivermectin vs. Standard of care; Outcome: viral clearance; Analysis: subgroups by control implemented.

	xperim vents		Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Control = HCQ Chowdhury et al Fixed effect model Random effects model Heterogeneity: not applicable	30	60 60	12	56 56	2	.33	[1.33; 4.09] [1.33; 4.09] [1.33; 4.09]	3.1% 3.1% 	5.4% 5.4%
Control = SOC Mahmud et al Ahmed et al Kirti et al Bukhari el al Mohan et al Biber et al Kishoria et al Okumus et al Pott-Junior et al Podder et al Vallejos et al Fixed effects model Random effects model Heterogeneity: $l^2 = 42\%$, $t^2 =$	169 18 13 20 33 34 8 14 17 18 113	183 45 55 41 80 47 19 16 27 20 240 773	144 3 18 14 21 6 3 2 19 120	180 23 57 45 45 42 13 8 3 20 241 677	3 	.07 .75 .22 .33 .45 .91 .33 .94 .95 .95 .11	[1.06; 1.26] [1.01; 9.34] [0.41; 1.38] [0.76; 1.96] [0.80; 2.20] [1.02; 2.05] [0.41; 2.01] [0.94; 5.82] [0.40; 2.21] [0.79; 1.13] [0.79; 1.14] [1.02; 1.21] [0.97; 1.26]	36.3% 1.0% 4.4% 4.3% 4.5% 5.6% 1.8% 1.0% 0.9% 4.8% 30.0% 94.5%	19.7% 1.7% 4.8% 6.9% 6.3% 9.9% 3.2% 2.5% 2.8% 16.3% 16.3% 16.0%
Control = Lopinavir–Ritor Babalola et al Fixed effect model Random effects model Heterogeneity: not applicable Fixed effect model Random effects model Heterogeneity: $I^2 = 56\%$, $t^2 =$ Test for subgroup differences Test for subgroup differences	26 0.0289 (fixed e	ffect):	$C_2^2 = 8.35$		p ⊕0202)0.5 1 2 5	.77 .77	[0.93; 3.36] [0.93; 3.36] [0.93; 3.36] [1.07; 1.27] [1.02; 1.38]	2.4% 2.4% 100.0%	4.4% 4.4%

Test for subgroup differences (random effects): $c_2^2 = 8.16$, df = 2 (p = 0.02)

S26 Figure. Comparison: ivermectin vs. Standard of care; Outcome: viral clearance; Analysis: subgroups by disease severity.

Study	Experimenta Events Tota		ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Severity = Mild to mod Chowdhury et al Mahmud et al Ahmed et al Kirti et al Bukhari el al Mohan et al Biber et al Kishoria et al Podder et al Vallejos et al Fixed effect model Random effects model Heterogeneity: $I^2 = 59\%$, t	30 6 169 18 18 4 13 5 20 4 33 8 34 4 18 2 113 24 79	3 144 5 3 5 18 1 18 0 14 7 21 9 6 0 19 0 120 0 120	56 180 23 57 45 45 42 13 20 241 722		1.15 - 3.07 0.75 1.22 1.33 1.45 0.91 0.95 0.95 1.14	$ \begin{bmatrix} 1.33; 4.09 \\ 1.06; 1.26 \\ 1.01; 9.34 \\ 0.41; 1.38 \\ 0.76; 1.96 \\ 1.02; 2.05 \\ 1.02; 2.$	3.1% 36.3% 1.0% 4.4% 4.3% 4.5% 5.6% 1.8% 4.8% 30.0% 95.7%	5.4% 19.7% 1.7% 4.8% 6.9% 6.3% 9.9% 3.2% 16.3% 16.3% 16.3% 90.3%
Severity = Mixed Babalola et al Pott-Junior et al Fixed effect model Random effects model Heterogeneity: $l^2 = 31\%$, t	26 4 17 2 6	2 7 7 2 9	20 3 23		0.94 1.54	[0.93; 3.36] [0.40; 2.21] [0.91; 2.62] [0.73; 2.58]	2.4% 0.9% 3.3%	4.4% 2.8% 7.2%
Severity = Severe to cr Okumus et al Fixed effect model Random effects model Heterogeneity: not applica	14 1 1		8 8		2.33	[0.94; 5.82] [0.94; 5.82] [0.94; 5.82]	1.0% 1.0% 	2.5% 2.5%
Fixed effect model Random effects model Heterogeneity: $l^2 = 56\%$, t Test for subgroup difference Test for subgroup difference	² = 0.0289, <i>p</i> < es (fixed effect	0.01): c ₂ ² = 3.48				[1.07; 1.27] [1.02; 1.38]	100.0% 	 100.0%

S27 Figure. Comparison: ivermectin vs. Standard of care; Outcome: viral clearance; Analysis: subgroups by outcome measurement time frame.

Study	Experime Events			ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Follow: > 7 days Chowdhury et al Mahmud et al Podder et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 86\%$,		60 183 20 263 , <i>p</i> < 0	12 144 19	56 180 20 256		1.15 0.95 1.2 1	[1.33; 4.09] [1.06; 1.26] [0.79; 1.13] [1.11; 1.33] [0.89; 1.65]	3.1% 36.3% 4.8% 44.2%	5.4% 19.7% 16.3% 41.5%
Follow: < or = 7 days Ahmed et al Babalola et al Kirti et al Bukhari el al Mohan et al Biber et al Kishoria et al Okumus et al Pott–Junior et al Vallejos et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 42\%$,		45 42 55 41 80 47 19 16 27 240 612	3 7 18 18 14 21 6 3 2 120	23 20 57 45 45 42 13 8 3 241 497		1.77 0.75 1.22 1.33 1.45 0.91 2.33 0.94 0.95 1.13	[1.01; 9.34] [0.93; 3.36] [0.41; 1.38] [0.76; 1.96] [0.80; 2.20] [1.02; 2.05] [0.41; 2.01] [0.94; 5.82] [0.40; 2.21] [0.79; 1.14] [0.99; 1.29] [0.98; 1.51]	1.0% 2.4% 4.4% 4.3% 4.5% 5.6% 1.8% 1.0% 0.9% 30.0% 55.8%	1.7% 4.4% 4.8% 6.9% 6.3% 9.9% 3.2% 2.5% 2.8% 16.0% 58.5%
Fixed effect model Random effects mode Heterogeneity: $l^2 = 56\%$, Test for subgroup different Test for subgroup different	$t^2 = 0.0289$, ces (fixed ef	ffect):	$c_1^2 = 0.81$				[1.07; 1.27] [1.02; 1.38]	100.0% 	 100.0%

S28 Figure. Comparison: ivermectin vs. Standard of care; Outcome: adverse events; Analysis: subgroups by intervention implemented.

Study	Experimental Events Total Eve	Control ents Total	Risk Ratio	RR	95%-CI	Weight Weight (fixed) (random)
Intervention = Ivermed Mahmud et al Fixed effect model Random effects mode Heterogeneity: not applica	2 183 183 I	0 180 180		- 4.92 [0	0.24; 101.73] 0.24; 101.74] 0.24; 101.73]	10.3% 15.1% 10.3% 15.1%
Intervention = Ivermed Krolewiecki et al Lopez-Medina et al Pott-Junior et al Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t^2	1 20 2 200 3 27 247	0 12 2 198 1 4 214		0.99 0.44 0.90	[0.08; 41.52] [0.14; 6.96] [0.06; 3.30] [0.25; 3.19] [0.22; 2.84]	12.7% 14.2% 41.2% 36.4% 35.7% 34.4% 89.7% 84.9%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t ² Test for subgroup difference Test for subgroup difference	$p^{2} = 0, p = 0.58$ ces (fixed effect): $c_{1}^{2} =$	394 = 1.03, df = 0.00 = 0 c ₁ ² = 1.18, df = 1 (<i>µ</i>	0.301) 1 10 0 = 0.28)		[0.43; 4.02] [0.32; 3.38]	100.0% 100.0%


S29 Figure. Comparison: ivermectin vs. Standard of care; Outcome: adverse events; Analysis: subgroups by control implemented.

Study	Experimental Events Total Ev	Control vents Total	Risk Ratio	RR 95	Weight 5%-CI (fixed)	Weight (random)
Control = SOC Mahmud et al Krolewiecki et al Lopez-Medina et al Pott-Junior et al Fixed effect model Random effects mode Heterogeneity: $l^2 = 0\%$, t'		0 180 0 12 2 198 1 4 394			41.52]12.7%6.96]41.2%3.30]35.7%4.02]100.0%	15.1% 14.2% 36.4% 34.4% 100.0%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$, t ² Test for subgroup different Test for subgroup different	$p^{2} = 0, p = 0.58$ ces (fixed effect): c_{0}^{2}			1.31 [0.43; 1.04 [0.32; 100	4.02] 100.0% 3.38]	 100.0%


S30 Figure. Comparison: ivermectin vs. Standard of care; Outcome: adverse events; Analysis: subgroups by disease severity.

Study	Experime Events			ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Severity = Mild to mode Mahmud et al Krolewiecki et al Lopez–Medina et al Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$, t^2	2 1 2	183 20 200 403 68	0 0 2	180 12 198 390			[0.24; 101.73] [0.08; 41.52] [0.14; 6.96] [0.45; 7.14] [0.38; 6.98]	12.7%	15.1% 14.2% 36.4% 65.6%
Severity = Mixed Pott-Junior et al Fixed effect model Random effects model Heterogeneity: not applicat		27 27	1	4 4		0.44 0.44 0.44	[0.06; 3.30] [0.06; 3.30] [0.06; 3.30]	35.7% 35.7% 	34.4% 34.4%
Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, t^2 Test for subgroup difference Test for subgroup difference	= 0, p = 0.5 ses (fixed effects)	ffect):	c ₁ ² = 1.26 ts): c ₁ ² = 1	394 [df =0.0 1.06, df =	μ = 0.265) 1 10 = 1 (ρ = 0.30)	1.31 1.04 100	[0.43; 4.02] [0.32; 3.38]		 100.0%

S31 Figure. Comparison: ivermectin vs. Standard of care; Outcome: mortality; Analysis: risk of publication bias.



S32 Figure. Comparison: ivermectin vs. Standard of care; Outcome: symptom resolution or improvement; Analysis: risk of publication bias.



S33 Figure. Comparison: ivermectin vs. Standard of care; Outcome: viral clearance; Analysis: risk of publication bias.

